Kit for detecting child medicamentous deaf inheritance risk

A drug-induced deafness and genetic risk technology, applied in the fields of molecular biology and medicine, can solve problems such as individual differences, toxicity sensitivity, and ototoxicity reactions

Inactive Publication Date: 2008-08-13
HAINAN ZHUJIAN BIOTECH
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in patients with deafness caused by aminoglycoside antibiotics, some patients are particularly sensitive to toxicity, and a small dose or even a single dose of the drug may cause deafness, and there are individual differences
Generally speaking, it is relatively safe to use this type of drug at a normal dose, but some patients have family genetic susceptibility and individual differences to this type of drug. Early or severe ototoxicity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Example 1. Use of detection kits

[0038] Step 1: Extraction of DNA template

[0039] Genomic DNA of oral epithelial cells was extracted by silica gel adsorption.

[0040] Step 2: PCR amplification reaction

[0041] Use the PCR reaction set in the detection kit, which contains the following primer pairs:

[0042] Sense primer 1: 5'-GCGTTTGGTCCTAGCCTTTC-3' (SEQ ID NO: 1)

[0043] Antisense primer 1: 5'-GCATCTTTCCCTTGCGGTAC-3' (SEQ ID NO: 2)

[0044] The reaction system has a total volume of 25 μl, including 1 μl of DNA template with a concentration of 12.5ng / μl, 2.5 μl of 10X PCR reaction buffer, 0.2 μl of 25mM dNTP mixture, 1.5 μl of 25mM MgCl2 solution, 0.125 μl of 5 units / μl Taq DNA polymerase, 0.25 μl of each primer for 20 μM specific primer pair, 19.175 μl of deionized water.

[0045] The reaction was carried out on an ABI2720 type PCR amplification instrument. The reaction conditions were 94°C, 12 minutes, and 30 cycles of 94°C, 30 seconds, 60°C, 30 seconds, 7...

Embodiment 2

[0057] Example 2. Services for genetic risk detection of susceptibility to drug-induced deafness in children

[0058] Step 1: DNA Extraction

[0059] The children under inspection were instructed by the laboratory physician of the hospital to use oral swabs to sample oral epithelial cells, and the silica gel adsorption method was used to extract the DNA of oral epithelial cells.

[0060] Step 2: Genotyping Assays

[0061] Using the kit provided by the present invention, the three SNP sites A1555G, U1494A, and T1095C on the MTRNR1 gene of the detected children's genomic DNA and the DEL 961T CINS site polymorphisms were detected by DNA sequencing, and the polymorphisms of these 4 sites were determined. polymorphic genotype.

[0062] Step 3: Analysis of the genetic risk of drug-induced deafness in children

[0063] Through the analysis of the polymorphic genotype of the tested subjects, an analysis report sheet of the genetic risk of susceptibility to drug-induced deafness in ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a agent box for detecting infant medicaments deafness heredity risks. The agent box comprises specificity primer and DNA sequencing primer for detecting four sites polymorphism on detection MTRNR1 gene, PCR reaction component and PCR outcome yield purifying component etc.. The agent box of the invention assesses infant medicaments deafness heredity risks by detecting four sites polymorphism on detection MTRNR1 gene correlative closely to infant medicaments deafness heredity risks.

Description

technical field [0001] The present invention relates to the fields of molecular biology and medicine. More specifically, the present invention relates to a kit for detecting the genetic risk of drug-induced deafness in children, and evaluates children's drugs by simultaneously detecting four polymorphic genotypes on the MTRNR1 gene. Genetic risk of deafness. Background technique [0002] At present, 20,000-30,000 deaf children are born in my country every year, 50% of which are caused by genetic factors. Deafness caused by adverse drug reactions is the main cause of congenital deafness in newborns and acquired deafness in adults. [0003] What is damaged by drug-induced deafness is not the sound conduction system of the outer ear and middle ear, that is, non-conductive deafness, but the hair cells of the cochlea, the most important and most vulnerable part of the perception of sound, are damaged by drug poison. Hair cells are the peripheral receptors of the auditory nerve....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68C12N15/11
Inventor 冯哲民邹祖烨
Owner HAINAN ZHUJIAN BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products